Role of STAT3 in Resistance of Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.07.08
- Author:
Sibo SUN
1
;
Shidai JIN
1
;
Renhua GUO
1
Author Information
1. Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
- Publication Type:Journal Article
- Keywords:
Acquired drug resistance;
Lung neoplasms;
STAT3 transcription factor
- From:
Chinese Journal of Lung Cancer
2019;22(7):457-463
- CountryChina
- Language:Chinese
-
Abstract:
The inflammatory state of tumor microenvironment play an important role in non-small cell lung cancer (NSCLC) drug resistance. As the key signal pathway connecting inflammation and tumor, activated signal transduction and transcriptional activation factor 3 (STAT3) leads togenetic abnormal expression, gene silencing, genomic instability, etc. in tumor cells, and induces therapeutic resistance. STAT3 has thepotential to be a new target for reversal of resistance. In this review, we summarize the progress of STAT3 in acquired drug resistance of NSCLC, explore the possibility of STAT3 as a new target to reverse drug resistance, and provide basic theories for the new clinical treatment strategy of acquired drug resistance in NSCLC.
.
